First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study

WANG Meng-zhao

doi:10.12019/j.issn.1671-5144.2023.04.003

WANG Meng-zhao. First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 203-207. DOI: 10.12019/j.issn.1671-5144.2023.04.003

Citation:

WANG Meng-zhao. First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 203-207. DOI: 10.12019/j.issn.1671-5144.2023.04.003

Citation:

WANG Meng-zhao. First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 203-207. DOI: 10.12019/j.issn.1671-5144.2023.04.003

First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study

WANG Meng-zhao

Graphical Abstract

Abstract

FullText(HTML)

References (14)

First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study

Catalog

Export File

Citation

Format

Content